Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2012

View Archived Issues

New phosphodiesterase 10A inhibitors discovered

Phase II trial of CTP-499 advances

FluoroPharma Medical plans phase II study of cardiac imaging agent

Icatibant acetate may improve acquired angioedema

New chemokine CCR8 receptor antagonists identified at AstraZeneca

Novel kinase inhibitors developed in Spain

Roche patents new candidate hepatitis C therapies

New renin inhibitors designed in China

Collaborating companies in Japan synthetize novel CKI inhibitors

Advinus Therapeutics announces novel glucokinase activators

Seglin OGA inhibitors show promise in vivo

Madrigal launches new phase I trial of cholesterol-lowering agent

EyeGate Pharma begins phase I trial in anterior scleritis

FDA supports initiation of pivotal DSC-127 trials

EMA grants orphan drug status to Cytokinetics drug in ALS

New Taisho drug has promising pharmacological profile

Novel SYK inhibitor shows potential as asthma therapeutic

Miraculins provides details on FDA's clearance of cholesterol test

Eisai receives complete response letter on Dacogen

Stem cell product set to be assessed in patients with artery disease

FDA approves Surfaxin

AcelRx advances patient-controlled analgesia system to phase III

More encouraging results reported on levomilnacipran in MDD

Michael J. Fox Foundation awards funding to QR Pharma

Abbott to develop companion diagnostic for Merck & Co. anticancer candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...